Invitrocue Ltd’s (ASX:IVQ) Onco-PDO test takes a personalised approach and allows physicians to prescribe the most appropriate treatment regime for a particular type of cancer.
The Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a broad panel of chemotherapy drugs to support personalised clinical decisions.
Invitrocue co-founder and executive director Dr. Steven Fang will present to investors at the Sydney investor event on Monday, May 13 and at the Melbourne event on Tuesday, May 14.
Dr. Steven Fang
The company recently signed a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB) for the development of new breast cancer models for its Onco-PDO test.
Under the agreement, professor Arial Zeng, an expert in stem cells during mammary development and breast cancer, will help Invitrocue to develop and optimise the protocols for the in vitro culture, propagation and expansion of patient-derived organoids (PDOs) from breast cancer patients with multiple breast cancer subtypes, including ER+, PR+, HER2+ and TNBC.
The intellectual property (IP) will be jointly owned by both parties and Invitrocue will be granted global commercialisation rights to any IP developed under the agreement.
Register for the CEO Sessions today